Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study.
Adult
Child
Child, Preschool
Cohort Studies
Diabetes, Gestational
/ epidemiology
Female
Humans
Infant, Newborn
Metformin
/ therapeutic use
Pediatric Obesity
/ epidemiology
Polycystic Ovary Syndrome
/ drug therapy
Pre-Eclampsia
/ epidemiology
Pregnancy
Pregnancy Complications
/ drug therapy
Pregnancy Outcome
/ epidemiology
Prenatal Exposure Delayed Effects
/ epidemiology
Prognosis
Risk Factors
Sweden
/ epidemiology
Treatment Outcome
Young Adult
Diabetes
Gestational
Metformin
Obesity
PCOS
Pre-eclampsia
Pregnancy
Journal
Reproductive biology and endocrinology : RB&E
ISSN: 1477-7827
Titre abrégé: Reprod Biol Endocrinol
Pays: England
ID NLM: 101153627
Informations de publication
Date de publication:
07 Feb 2022
07 Feb 2022
Historique:
received:
19
11
2021
accepted:
30
01
2022
entrez:
8
2
2022
pubmed:
9
2
2022
medline:
24
3
2022
Statut:
epublish
Résumé
Polycystic Ovary Syndrome (PCOS) is an endocrine disorder that affects women in reproductive age and represents an unfavourable risk factor for several pregnancy and perinatal outcomes. Despite, no guidelines or pharmaceutical strategies for treating PCOS during pregnancy are available. The aim of this study is to determine the association between polycystic ovary syndrome with or without metformin and the pregnancy, perinatal outcomes as well as the risk of obesity in children born to these mothers. In this nationwide population-based cohort study based in Swedish population, all singleton births (n = 1,016,805) from 686,847 women since 2006 up to 2016 were included. Multivariable logistic and Cox regression modelling with odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals were used to study the association between the exposure of maternal PCOS, metformin during pregnancy (or the combination of both) and: 1) Pregnancy outcomes: preeclampsia, gestational diabetes, caesarean section, and acute caesarean section, 2) Perinatal outcomes: preterm birth, stillbirth, low birth weight, macrosomia, Apgar < 7 at 5 min, small for gestational age and large for gestational age, and 3) Childhood Obesity. PCOS in women without metformin use during pregnancy was associated with higher risks of preeclampsia (OR = 1.09, 1.02-1.17), gestational diabetes (OR = 1.71, 1.53-1.91) and caesarean section (OR = 1.08, 1.04-1.12), preterm birth (OR = 1.30, 1.23-1.38), low birth weight (OR = 1.29, 1.20-1.38), low Apgar scores (OR = 1.17, 1.05-1.31) and large for gestational age (OR = 1.11, 1.03-1.20). Metformin use during pregnancy (in women without PCOS) was associated with a 29% lower risks of preeclampsia (OR = 0.71, 0.51-0.97), macrosomia and large for gestational age. Obesity was more common among children born to mothers with PCOS without metformin (HR = 1.61, 1.44-1.81); and those with metformin without PCOS (HR = 1.67, 1.05-2.65). PCOS with metformin was not associated with any adverse outcome. PCOS was associated with increased risks of adverse pregnancy and perinatal outcomes and childhood obesity. Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS.
Sections du résumé
BACKGROUND
BACKGROUND
Polycystic Ovary Syndrome (PCOS) is an endocrine disorder that affects women in reproductive age and represents an unfavourable risk factor for several pregnancy and perinatal outcomes. Despite, no guidelines or pharmaceutical strategies for treating PCOS during pregnancy are available. The aim of this study is to determine the association between polycystic ovary syndrome with or without metformin and the pregnancy, perinatal outcomes as well as the risk of obesity in children born to these mothers.
METHODS
METHODS
In this nationwide population-based cohort study based in Swedish population, all singleton births (n = 1,016,805) from 686,847 women since 2006 up to 2016 were included. Multivariable logistic and Cox regression modelling with odds ratios (OR) and hazard ratios (HR) and 95% confidence intervals were used to study the association between the exposure of maternal PCOS, metformin during pregnancy (or the combination of both) and: 1) Pregnancy outcomes: preeclampsia, gestational diabetes, caesarean section, and acute caesarean section, 2) Perinatal outcomes: preterm birth, stillbirth, low birth weight, macrosomia, Apgar < 7 at 5 min, small for gestational age and large for gestational age, and 3) Childhood Obesity.
RESULTS
RESULTS
PCOS in women without metformin use during pregnancy was associated with higher risks of preeclampsia (OR = 1.09, 1.02-1.17), gestational diabetes (OR = 1.71, 1.53-1.91) and caesarean section (OR = 1.08, 1.04-1.12), preterm birth (OR = 1.30, 1.23-1.38), low birth weight (OR = 1.29, 1.20-1.38), low Apgar scores (OR = 1.17, 1.05-1.31) and large for gestational age (OR = 1.11, 1.03-1.20). Metformin use during pregnancy (in women without PCOS) was associated with a 29% lower risks of preeclampsia (OR = 0.71, 0.51-0.97), macrosomia and large for gestational age. Obesity was more common among children born to mothers with PCOS without metformin (HR = 1.61, 1.44-1.81); and those with metformin without PCOS (HR = 1.67, 1.05-2.65). PCOS with metformin was not associated with any adverse outcome.
CONCLUSION
CONCLUSIONS
PCOS was associated with increased risks of adverse pregnancy and perinatal outcomes and childhood obesity. Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS.
Identifiants
pubmed: 35130922
doi: 10.1186/s12958-022-00905-6
pii: 10.1186/s12958-022-00905-6
pmc: PMC8819934
doi:
Substances chimiques
Metformin
9100L32L2N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Informations de copyright
© 2022. The Author(s).
Références
N Engl J Med. 2016 Feb 4;374(5):434-43
pubmed: 26840133
Hum Reprod. 2019 Oct 2;34(10):2052-2060
pubmed: 31504532
JAMA Pediatr. 2019 Feb 1;173(2):160-168
pubmed: 30508164
Lancet Diabetes Endocrinol. 2020 Oct;8(10):834-844
pubmed: 32946820
Lancet Diabetes Endocrinol. 2015 Oct;3(10):778-86
pubmed: 26165398
Diabetologia. 2019 Jun;62(6):1024-1035
pubmed: 30904939
Int J Environ Res Public Health. 2018 Nov 20;15(11):
pubmed: 30463276
Fertil Steril. 2019 Mar;111(3):588-596.e1
pubmed: 30630591
Nature. 2013 Feb 14;494(7436):256-60
pubmed: 23292513
Nat Rev Endocrinol. 2019 Oct;15(10):569-589
pubmed: 31439934
J Obstet Gynaecol. 2018 Aug;38(6):750-755
pubmed: 29537320
Gynecol Endocrinol. 2003 Feb;17(1):51-6
pubmed: 12724019
Cell Metab. 2021 Mar 2;33(3):513-530.e8
pubmed: 33539777
BMC Med. 2010 Jun 30;8:41
pubmed: 20591140
Hum Reprod. 2007 Nov;22(11):2967-73
pubmed: 17766923
J Obstet Gynaecol Res. 2018 Jan;44(1):81-86
pubmed: 29094444
Nat Rev Endocrinol. 2018 Oct;14(10):570-572
pubmed: 30120391
Nat Med. 2018 Jun;24(6):834-846
pubmed: 29760445
BMJ Open Diabetes Res Care. 2018 Apr 13;6(1):e000456
pubmed: 29682291
Reprod Toxicol. 2018 Oct;81:79-83
pubmed: 30017588
Pharmacoepidemiol Drug Saf. 2019 Dec;28(12):1609-1619
pubmed: 31693269
J Hum Reprod Sci. 2018 Oct-Dec;11(4):348-352
pubmed: 30787519
Obstet Gynecol. 2015 Jun;125(6):1397-1406
pubmed: 26000511
Scand J Clin Lab Invest. 2012 Nov;72(7):570-5
pubmed: 22935043
Eur Rev Med Pharmacol Sci. 2017 Aug;21(15):3482-3489
pubmed: 28829492
Hum Reprod. 2004 Aug;19(8):1734-40
pubmed: 15178665
J Womens Health (Larchmt). 2017 Aug;26(8):836-848
pubmed: 28570835
Nutr Diabetes. 2020 Jan 22;10(1):4
pubmed: 32066661
Obes Rev. 2019 May;20(5):659-674
pubmed: 30674081
Electron Physician. 2017 Dec 25;9(12):5969-5973
pubmed: 29560149
Lancet Child Adolesc Health. 2019 Mar;3(3):166-174
pubmed: 30704873
Rev Bras Ginecol Obstet. 2018 Apr;40(4):180-187
pubmed: 29702716
BJOG. 2015 Sep;122(10):1295-302
pubmed: 25761516
BMC Pregnancy Childbirth. 2014 May 31;14:185
pubmed: 24884711
Obes Rev. 2019 Jun;20(6):842-858
pubmed: 30785659
N Engl J Med. 2008 May 8;358(19):2003-15
pubmed: 18463376
Am J Obstet Gynecol. 2011 Jun;204(6):558.e1-6
pubmed: 21752757
Curr Med Res Opin. 2013 Jan;29(1):55-62
pubmed: 23205605
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1612-1621
pubmed: 29490031
Minerva Ginecol. 2017 Apr;69(2):141-149
pubmed: 27310674
BMC Pregnancy Childbirth. 2019 Nov 1;19(1):398
pubmed: 31675922
J Clin Endocrinol Metab. 2014 Aug;99(8):2942-51
pubmed: 24873996
Int J Endocrinol. 2020 Sep 16;2020:5150684
pubmed: 33014044
Obstet Gynecol. 2015 Nov;126(5):978-986
pubmed: 26444129
Iran J Reprod Med. 2012 May;10(3):265-70
pubmed: 25243003
Hum Reprod Update. 2015 Sep-Oct;21(5):575-92
pubmed: 26117684
BMJ. 2011 Oct 13;343:d6309
pubmed: 21998337
Diabet Med. 2006 Mar;23(3):318-22
pubmed: 16492217
Endocrine. 2019 Nov;66(2):192-200
pubmed: 31401725
J Diabetes Res. 2015;2015:341583
pubmed: 26064978
J Endocr Soc. 2020 Nov 16;5(2):bvaa177
pubmed: 33381671
Int J Gynaecol Obstet. 2008 Jul;102(1):39-43
pubmed: 18321516
Fertil Steril. 2012 Jan;97(1):218-24
pubmed: 22088206
Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):63-6
pubmed: 21530058
Diabet Med. 2018 Feb;35(2):160-172
pubmed: 29044702
Cochrane Database Syst Rev. 2020 Jun 11;6:CD012394
pubmed: 32526091
BJOG. 2014 Apr;121(5):575-81
pubmed: 24418062
Eur J Obstet Gynecol Reprod Biol. 2010 Mar;149(1):31-6
pubmed: 20056308
Lancet Diabetes Endocrinol. 2019 Apr;7(4):256-266
pubmed: 30792154
Am J Obstet Gynecol. 2017 Sep;217(3):282-302
pubmed: 28619690
Pharmacoepidemiol Drug Saf. 2007 Jul;16(7):726-35
pubmed: 16897791
Hum Reprod Update. 2014 Nov-Dec;20(6):853-68
pubmed: 25013215
Diabet Med. 2004 Aug;21(8):829-36
pubmed: 15270785
Hum Reprod. 2005 Aug;20(8):2122-6
pubmed: 15802312
PLoS Med. 2019 Aug 6;16(8):e1002848
pubmed: 31386659